Objective response

You have access
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
Laure Al Mansour, Louis De Mestier, Magalie Haissaguerre, Pauline Afchain, Julien Hadoux, Thierry Lecomte, David Morland, Anne Segolene Cottereau, Ophelie De Rycke, Ghoufrane Tlili, Jérémie Tordo, Marc Janier, Agathe Deville and Thomas Walter

Journal of Nuclear Medicine February 1, 2024, 65 (2) 258-263; DOI: https://doi.org/10.2967/jnumed.123.266063
You have access
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant ²²⁵Ac-DOTATATE–Targeted α-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study
Sanjana Ballal, Madhav P. Yadav, Madhavi Tripathi, Ranjit Kumar Sahoo and Chandrasekhar Bal

Journal of Nuclear Medicine February 1, 2023, 64 (2) 211-218; DOI: https://doi.org/10.2967/jnumed.122.264043

Main menu